The US Bankruptcy Court granted a second order for the extension of the exclusivity periods for PhaseBio Pharmaceuticals, Inc. on July 10, 2023. As per the order, the debtor?s exclusivity period to file its plan and to solicit votes on its plan, have been extended by 90 days i.e. up to August 21, 2023 and October 18, 2023, respectively.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | 0.00% | 0.00% | 0.00% |
1st Jan change | Capi. | |
---|---|---|
0.00% | 49 | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- PHAS.Q Stock
- News PhaseBio Pharmaceuticals, Inc.
- Second Motion for Exclusivity Period Extension Approved For PhaseBio Pharmaceuticals, Inc.